versione pdf - Sistema Nazionale Linee Guida

Iperplasia prostatica benignaBibliografia essenziale1 Chicharro Molero JA, Burgos Rodriguez R,Sanchez Cruz JJ, del Rosal-Samaniego JM,Rodero-Carcia P, Rodriguez-Vallejo JM. Prevalenceof benign prostatic hyperplasia in Spanishmen 40 years old or older. J Urol 1998;159:878-82.2 Verhamme KM, Dieleman JP, Bleumink GS, Vander Lei J, Sturkenboom MC, Artibani W for TriumphPan European Expert Panel. Incidence andprevalence of lower urinary tract symptoms suggestiveof benign prostatic hyperplasia in primarycare - The Triumph project. European Urol2002;42:323-8.3 Ukimura O, Kojima M, Inui E, Ochiai A, Hata Y,Watanabe M, et al. A statistical study of theAmerican Urological Association symptom indexfor benign prostatic hyperplasia in participantsof mass screening program for prostatic diseasesusing transrectal sonography. J Urol1996;156:1673-8.4 Collins MF, Friedman RH, Ash A, Hall R,Moskowitz MA. Underdetection of clinical benignprostatic hyperplasia (BPH) in a general medicalpractice. J Gen Intern Med 1996;11:513-8.5 Wille-Gussenhoven MJ, de Bock GH, de Beer-Buijs, Burgers SM, Buurman CM, Evenaar M, etal. Prostate symptoms in general practice: seriousnessand inconvenience. Scand J Prim HealthCare 1997;15:39-42.6 Norman RW, Nickel JC, Fish D, Pickett SN.‘Prostate-related symptoms’ in Canadian men 50years of age or older: prevalence and relationshipsamong symptoms. Br J Urol 1994;74:542-50.7 Madersbacher S, Haidinger G, Temml C,Schmidbauer CP. Prevalence of lower urinarytract symptoms in Austria as assessed by anopen survey of 2096 men. Eur Urol 1998;34:136-41.8 Trueman P, Hood SC, Nayak US, Mrazek MF.Prevalence of lower urinary tract symptoms andself-reported diagnosed ‘benign prostatic hyperplasia’,and their effect on quality of life in a community-basedsurvey of men in the UK. BJU Int1999;83:410-5.9 Lukacs B. Management of symptomatic BPH inFrance: who is treated and how? Eur Urol1999;36(suppl 3):14-20.10 Clifford GM, Logie J, Farmer RD. How do symptomsindicative of BPH progress in real life practice?The UK experience. Eur Urol 2000;38(suppl1):48-53.11 Treagust J, Morkane T, Speakman M. Estimatinga population’s needs for the treatment of lowerurinary tract symptom in men: what is the extentof unmet need? J Public Health Med 2001;23:141-7.12 Berges RR, Pientka L, Hofner K, Senge T, JonasU. Male lower urinary tract symptoms and relatedhealth care seeking in Germany. Eur Urol2001;39:682-7.13 Hassler E, Krakau I, Haggarth L, Norlen L, EkmanP. Questioning questions about symptoms ofbenign prostatic hyperplasia. Fam Pract 2001;18:328-32.14 The GC, Sahabudin RM, Lim TC, Chong WL,Woo S, Mohan M, et al. Prevalence of symptomaticBPE among Malaysian men aged 50 andabove attending screening during prostate healthawareness campaign. Med J Malaysia 2001;56:186-95.15 Flam T, Montauban V. Screening of clinical benignprostatic hypertrophy in general practice: surveyof 18,540 men. Prog Urol 2003;13:416-24.16 Tuncay Aki F, Aygun C, Bilir N, Erkan I, Ozen H.Prevalence of lower urinary tract symptoms in acommunity-based survey of men in Turkey. Int JUrol 2003;10:364-70.17 Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B,Meuleman E, et al. Lower urinary tract symptomsand male sexual disfunction: the multinationalsurvey of the aging male (MSAM-7). Eur Urol2003; 44:637-49.18 Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C.Recent trends in mortality from benign prostatichyperplasia. Prostate 2003;56:207-11.19 Pagliarulo A, de Rienzo G. Come si è modificatal’interpretazione fisiopatologia della IPB.Bollettino di Informazioni Medico-Statistiche,2003: 122.20 Osservatorio Nazionale sull’Impiego dei Medicinali.L’uso dei farmaci in Italia – RapportoNazionale Anno 2003. Ministero della Salute.Roma, Italy: Il Pensiero Scientifico Editore, 2004.21 Dati ISTAT. www.demo.istat.it/previsioni/index.html, accesso 15 aprile 2004.22 Project Writing Committee. The national programmefor guidelines. www.pnlg.it/doc/pnlgx_eng(accesso 4 aprile 2003).23 Programma nazionale per le linee guida. Manualemetodologico. Come produrre, diffonderee aggiornare raccomandazioni per la praticaclinica. 2002, aggiornamento 2004. http://www.pnlg.it/doc/Manuale_PNLG.pdf, accesso22 novembre 2005.24 AA.VV. Undertaking systematic reviews ofresearch on effectiveness: CRD’s guidance forthose carryng out or commisioning reviews, 2 ndedition. www.york.ac.uk/inst/crd, accesso 4aprile 2003.25 Linee Guida: Metodologia: Schema di gradingCeVEAS. www.ceveas.it/ceveas/viewPage. do?idp=209, accesso 4 aprile 2003.26 Shiffman RN, Shekelle P, Overhage JM, SlutskyJ, Grimshaw J, Deshpande AM. Standardizedreporting of clinical practice guidelines: a proposalfrom the Conference on Guideline Standardization.Ann Intern Med 2003;139:493-8.27 American Urological Association. Guideline onthe management of benign prostatic hyperplasia(BPH), 2003. www.auanet.org/timssnet/products/guidelines/bph_management,accesso 24maggio 2003.36Bibliografia essenziale